As our understanding of TG metabolism deepens and with the increasing availability of a range of LPL regulator-based drugs, we anticipate greater precision in controlling TG metabolism in patients, and thus this holistic approach holds promise for improving the management of metabolic syndromes and related conditions. The gene discussed is LPL; the disease is metabolic syndrome.